Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 89, Issue 3, 2018, Pages 271-276

  Lee, Eun Jae ^a   Oh, Mi Sun ^b   Kim, Jong S ^a   Chang, Dae Il ^c   Park, Jong Ho ^d   Cha, Jae Kwan ^e   Heo, Ji Hoe ^f   Sohn, Sung Il ^g   Kim, Dong Eog ^h   Kim, Hahn Young ⁱ   Kim, Jei ^j   Seo, Woo Keun ^k   Lee, Jun ^l   Park, Sang Won ^m   Kim, Yun Joong ^b   Lee, Byung Chul ^b  

^a University of Ulsan   (South Korea)

^b Hallym University   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Seonam University   (South Korea)

^e Dong A University College of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Dongsan Medical Center   (South Korea)

^h Dongguk University Ilsan Hospital   (South Korea)

ⁱ Konkuk University School of Medicine   (South Korea)

^j Chungnam National University College of Medicine   (South Korea)

^k Korea University College of Medicine   (South Korea)

^l Young Nam University Hospital   (South Korea)

^m Daegu Fatima Hospital   (South Korea)

more..

Author keywords

genedepression; motor recovery; serotonin; stroke

Indexed keywords

ESCITALOPRAM; PLACEBO; SEROTONIN TRANSPORTER; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR; SLC6A4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL OUTCOME; COGNITION; CONTROLLED STUDY; CONVALESCENCE; DEPRESSION; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG USE; EMOTIONAL DISORDER; FEMALE; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; PHARMACOGENETICS; POST HOC ANALYSIS; POSTSTROKE NEUROLOGICAL RECOVERY; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RISK FACTOR; SERT GENE; TREATMENT DURATION; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOGENETIC VARIANT; PSYCHOLOGY;

AGED; CITALOPRAM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 85042882639     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2017-316882     Document Type: Article

References (40)

1. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007;18:391-418.
2. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9.
3. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;20:9104-10.
4. Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. Lancet Neurol 2011;10:123-30.
5. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211-4.
6. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008;22:311-4.
7. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718-29.
8. Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010;67:187-96.
9. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: A meta-analysis. Int J Clin Pract 2010;64:1310-7.
10. Mikami K, Jorge RE, Adams HP, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry 2011;19:1007-15.
11. Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012;11:Cd009286.
12. Robinson RG, Jorge RE. Post-stroke depression: Review. Am J Psychiatry 2016;173:221-31.
13. Canli T, Lesch KP. Long story short: The serotonin transporter in emotion regulation and social cognition. Nat Neurosci 2007;10:1103-9.
14. Battersby S, Ogilvie AD, Smith CA, et al. Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet 1996;6:177-82.
15. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-4.
16. McGuffin P, Alsabban S, Uher R. The truth about genetic variation in the serotonin transporter gene and response to stress and medication. Br J Psychiatry 2011;198:424-7.
17. Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol Psychiatry 2004;9:433-41.
18. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473-500.
19. Kim JS, Lee EJ, Chang DI, et al.Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: A multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry 2017;4:33-41.
20. Kearns NP, Cruickshank CA, McGuigan KJ, et al. A comparison of depression rating scales. Br J Psychiatry 1982;141:45-9.
21. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9.
22. Kohen R, Cain KC, Mitchell PH, et al. Association of serotonin transporter gene polymorphisms with poststroke depression. Arch Gen Psychiatry 2008;65:1296-302.
23. Lovejoy EA, Scott AC , Fiskerstrand CE, et al. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur J Neurosci 2003;17:417-20.
24. Fiskerstrand CE, Lovejoy EA, Quinn JP. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 1999;458:171-4.
25. MacKenzie A, Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 1999;96:15251-5.
26. Wallis DI. 5-HT receptors involved in initiation or modulation of motor patterns: Opportunities for drug development. Trends Pharmacol Sci 1994;15:288-92.
27. Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Neurobiol 1997;7:820-5.
28. Lim CM, Kim SW, Park JY, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009;87:1037-45.
29. Li J, Wang Y, Zhou R, et al. Association between polymorphisms in serotonin transporter gene and attention deficit hyperactivity disorder in Chinese Han subjects. Am J Med Genet B Neuropsychiatr Genet 2007:144B:14-19.
30. Yue W, Liu H, Zhang J, et al. Association study of serotonin transporter gene polymorphisms with obstructive sleep apnea syndrome in Chinese Han population. Sleep 2008;31:1535-41.
31. Kim JM, Stewart R, Kang HJ, et al. Associations of serotonergic genes with poststroke emotional incontinence. Int J Geriatr Psychiatry 2012;27:799-806.
32. Choi-Kwon S, Han K, Cho KH, et al. Factors associated with post-stroke anger proneness in ischaemic stroke patients. Eur J Neurol 2013;20:1305-10.
33. Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 2009;9:61-70.
34. Saiz PA , Garcia-Portilla MP, Florez G, et al. Differential role of serotonergic polymorphisms in alcohol and heroin dependence. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:695-700.
35. Pizzo de Castro MR, Vargas Nunes SO, Guembarovski RL, et al. STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. J Affect Disord 2015;172:347-54.
36. Baca-Garcia E, Vaquero-Lorenzo C, Diaz-Hernandez M, et al. Association between obsessive-compulsive disorder and a variable number of tandem repeats polymorphism in intron 2 of the serotonin transporter gene. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:416-20.
37. Kim JS. Post-stroke mood and emotional disturbances: Pharmacological therapy based on mechanisms. J Stroke 2016;18:244-55.
38. Hashioka S, Klegeris A, Monji A, et al. Antidepressants inhibit interferon-gammainduced microglial production of IL-6 and nitric oxide. Exp Neurol 2007;206:33-42.
39. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999;22:391-7.
40. Mak KK, Kong WY, Mak A, et al. Polymorphisms of the serotonin transporter gene and post-stroke depression: A meta-analysis. J Neurol Neurosurg Psychiatry 2013;84:322-8.